The recall notice is easy to miss. Apothecary Pharma, a compounding pharmacy in Cary, North Carolina, voluntarily pulled 22 vials of compounded tirzepatide in late September because it could not assure that the product was sterile. The Food and Drug Administration classified the recall as Class II this month, a category that means exposure may cause temporary or medically reversible harm, with the probability of serious injury considered low. No infections have been linked to the vials.
The number is small. The paper trail is not. The same facility received a warning letter from the FDA in December after inspectors found serious deficiencies in its sterile production practices. The agency rejected the company's proposed fixes. The company had stopped sterile production in May 2025 and restarted it in August 2025 without what the FDA considered adequate interim controls. Eight months later, it was recalling vials for the same underlying concern.
That sequence is the story. A recall of 22 vials is a quality-control event. A recall of 22 vials from a facility that had already been told its sterile process was unsafe is a regulatory event. And a recall in a market that exists because of a drug shortage, after the shortage has largely ended, is a question about why the market is still there.
A small recall with a long paper trail
The recall covers compounded tirzepatide injection at 18 milligrams per milliliter in 4 milliliter sterile multidose vials, national drug code 85091-001-18. The affected lots run from AP-202622 through AP-202625 and from AP-202627 through AP-202644, with beyond-use dates spanning October 7 to November 26, 2026. The same notice includes one vial of Apothecary NAD+ injection at 200 milligrams per milliliter, lot AP-202647, recalled for the same reason. The total is 23 vials.
The company initiated the recall on September 24 and notified customers by letter. The FDA's enforcement report lists the recall as ongoing. The agency's classification, which came in early October, does not mean the product was found to be contaminated. It means the company could not demonstrate that it was sterile, and the agency graded the potential harm. For patients, the practical advice is narrow: check the lot number and beyond-use date, stop using an affected vial, and contact a prescriber or pharmacist. The brand-name versions of tirzepatide, sold as Mounjaro and Zepbound, are not part of the recall.
Compounded drugs are not generic versions of approved products. They are made by pharmacies or outsourcing facilities, and they do not go through the FDA's review for safety, effectiveness or manufacturing quality. That is the tradeoff patients accept when they buy one. The appeal is price and access. The risk is that the quality control is only as good as the facility making the vial.
What the warning letter found
The December 1, 2025 warning letter to Apothecary Pharma is unusually detailed. FDA inspectors visited the facility in September 2024 and again in January and May 2025. The letter describes operators blocking critical airflow with their bodies, resting forearms on surfaces inside the ISO 5 hood, leaning into the hood while working, wearing safety glasses instead of cleanroom goggles, and wearing masks upside down. It describes a rusty laminar airflow hood with peeling paint, missing dynamic smoke studies, gaps in disinfection and environmental monitoring, incomplete batch records, and a visual inspection process with no defect classification.
The agency's conclusion was blunt. It found serious deficiencies in the practices for producing sterile drug products, deficiencies that put patients at risk. It also cited labeling problems, including missing active ingredients, quantities, directions for use and adverse event reporting information.
The company told the FDA that it had stopped sterile operations on May 12, 2025, and resumed on August 1, 2025. The agency found the restart inadequate. Its review of the company's responses cited missing root-cause analyses, no retrospective batch review, incomplete vendor qualification, inadequate documentation and no evidence that the corrections would work. The FDA recommended a comprehensive third-party assessment. The recall followed.
A warning letter is not a recall, and a recall is not a finding that anyone was harmed. The legal significance is different. The letter establishes that the agency had put the company on notice about the specific practices that the recall later called into question. The company had a chance to fix the process before the vials shipped. The recall is what happened instead.
The shortage was the permission slip
Compounding exists in a narrow lane under federal law. Section 503A of the Food, Drug and Cosmetic Act allows licensed pharmacies to compound for individual patients with a prescription. Section 503B allows outsourcing facilities to make larger batches, but with more FDA oversight. Neither lane permits a pharmacy to make a copy of a commercially available approved drug. The exception is a drug shortage. When the FDA lists a product as in shortage, compounding pharmacies may make copies to fill the gap.
That is how compounded GLP-1s became a mass market. Tirzepatide and semaglutide were on the shortage list, demand for weight-loss drugs was surging, and the branded products were expensive and hard to find. Compounding pharmacies stepped in with cheaper copies. Patients who could not get Zepbound or Wegovy, or could not afford it, found a vial with a pharmacy label and a monthly price that was often far below the list price of the brand.
The arrangement was always temporary in theory. The FDA's shortage list is a statement about supply, not a permanent authorization. When the shortage ends, the permission ends with it. The agency has said as much in guidance, and it has moved to tighten the rules for these products, including a proposal to exclude them from the bulks list that outsourcing facilities rely on. The compounding industry has pushed back, arguing that patients still need access and that the branded supply is not reliable for everyone.
What changed when the shortage ended
The shortage has largely ended. The FDA removed tirzepatide and semaglutide from the list, and the agency has said that most of the drug shortages that justified compounding are over. What has not ended is the market. Compounding pharmacies have not scaled down at the same pace, and patients who started on a compounded product do not automatically switch back to a brand.
That gap between the legal permission and the commercial reality is where the recall becomes more than a single facility's problem. A pharmacy that is no longer authorized to make a copy of a drug is not supposed to keep making it. A patient who is used to a cheaper vial is not automatically willing to pay the list price for the brand. The result is a market that is legally narrower than it was but commercially larger than the rules contemplate.
The FDA's enforcement tools are limited. It can inspect, warn, classify recalls and propose rules. It cannot instantly shut down every facility that keeps compounding after a shortage ends, and it cannot force patients back to branded products. The agency's leverage is the warning letter and the recall, which is why the Apothecary Pharma file matters. It shows what happens when a facility with a known sterile-process problem stays in a market whose legal basis has narrowed.
Sterility is the business-model problem
Sterility is not a detail in injectable manufacturing. It is the product. A vial that is not sterile can cause a local infection, a bloodstream infection or worse, and the patients most likely to use compounded GLP-1s are often the ones with the least margin for a complication. The FDA's inspection findings at Apothecary Pharma were not about paperwork. They were about airflow, gowning, surface contact and environmental monitoring, the physical controls that keep microorganisms out of a vial.
Those controls are expensive. A compliant sterile operation needs cleanrooms, validated airflow, trained staff, environmental monitoring, batch records and a quality system that can catch a failure before the product ships. A compounding pharmacy that competes on price has an incentive to spend as little as it can on those controls. The FDA's warning letter describes what that incentive looks like when it goes too far.
The recall is small enough that it will not change the market on its own. Twenty-two vials are a rounding error against the millions of GLP-1 prescriptions written each year. But the file is a template. It shows the sequence that regulators will use: inspect, warn, reject the response, classify the recall, and let the enforcement record speak. The next facility may not get a warning letter first.
The patient's problem is the lot number
For a patient holding a vial, the national debate about compounding is less useful than the label. The recall notice lists the lots and the beyond-use dates. A patient who has a vial from Apothecary Pharma should check whether the lot falls in the affected range and whether the beyond-use date is still open. If it does, the advice is to stop using it and call the prescriber or pharmacist. The FDA says there have been no confirmed infections, which is reassuring but not a reason to keep using a recalled vial.
The larger advice is about sourcing. A compounded GLP-1 is not the same product as Mounjaro or Zepbound, even when the active ingredient is the same. The concentration, the vial, the preservative and the sterility controls can differ. A patient who switches between a brand and a compound, or between two compounders, is changing the manufacturing process, not just the price. That is worth knowing before the next vial is opened.
The market will keep testing the boundary. The FDA will keep inspecting and classifying. The recalls will keep coming in small batches, most of them unnoticed. The Apothecary Pharma file is worth noticing because it connects the three parts that usually stay separate: a facility's inspection history, a market's legal basis, and a patient's lot number. The first two are policy. The third is the one a patient can act on.